EUDA

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, March 19, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it will implement a reverse stock split of its ordinary shares at a ratio of 1-for-20 (the "Reverse Stock Split"). The Reverse Stock Split was approved by the Company's Board of Directors in accordance with British Virgin Islands law. The Reverse Stock Split will take effect at market open on March 23, 2026, and the ordinary shares will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol "EUDA" and will con

3 - EUDA Health Holdings Ltd (0001847846) (Issuer)

3 - EUDA Health Holdings Ltd (0001847846) (Issuer)

3 - EUDA Health Holdings Ltd (0001847846) (Issuer)

3 - EUDA Health Holdings Ltd (0001847846) (Issuer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC. Background of the Warrant As previously disclosed, the Company entered into a securities purchase agreement dated November 26, 2025 with an accredited investor for the purchase of a warrant that was immediately exercisable into up to 2,000,000 newly issued ordinary shares of the Company. The warrant was previously amended on December 16, 2025 and Januar

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)

424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has entered into a second amendment to its previously disclosed warrant agreement with Streeterville Capital, LLC. Summary of Second Warrant Amendment Terms Under the terms of the Second Warrant Amendment dated January 13, 2026, the Company and Streeterville Capital agreed to further reduce the exercise price of the warrant from US$4.00 per share to US$2.00 per share. In addition, the minimum closing price of the Company's ordinary shares required to t

424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) --  EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. ("EUDA Health"), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. ("Shenzhen Inno"), a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China. Strategic Investment and Facility Expansion Plan Under the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche o

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) "EUDA" or "the Company", a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered into an amendment (the "Warrant Amendment") to its previously disclosed warrant agreement with Streeterville Capital, LLC ("Streeterville Capital"). Background on the Original Warrant Transaction As previously announced, on November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital, a Utah limited liability company, for the issuance of a warrant (the "Warrant") exercisable into up to 2,000,000 newly issu

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) "EUDA" or "the Company," a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced the launch of its nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China. The Company has partnered with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital as the Company continues to expand its national clinical and logistics network. This platform marks a major step in EUDA's continued advancement of its stem cell strategy, further extending its capabilities across cell extraction, processing, cryogenic storage, logistic

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, Dec. 29, 2025 (GLOBE NEWSWIRE) --  EUDA Health Holdings Limited (NASDAQ:EUDA) "EUDA" or "the Company", a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it will launch EUDA Helixé 2.0 in January 2026, marking the next generation upgrade of its premium youthful vitality and longevity supplement. EUDA Helixé 2.0 introduces enhancements across formulation strength, ingredient technology, delivery systems, packaging design, and global market readiness. Strengthened Formula and Ingredient Optimization EUDA Helixé 2.0 features a 20% increase in New Zealand sourced deer placenta powder, with dosage enhanced from

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, Dec. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) "EUDA" or "the Company", a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced a significant acceleration of its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and establishment of its first clinic in Shenzhen, China. This strategic advancement builds on the Company's earlier acquisition of distribution rights for T-cell immunotherapies developed by Shenzhen Inno Immune Co. Ltd. ("Shenzhen Inno"), a developer of autologous cellular therapeutic and customized medicines for a wide r